Profound Medical (NASDAQ:PROF; TSX:PRN) and TrillaMed, a Service-Disabled Veteran-Owned Business (SDVOSB), have announced a partnership to support the federal deployment of TULSA-PRO—the MRI-guided, incision-free...
AC Immune (NASDAQ:ACIU) announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn trial evaluating ACI-7104.056—its anti-alpha-synuclein (a-syn) active immunotherapy candidate—for the...
Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...
Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”. The company is developing therapeutics to address mental illnesses related...
Leap Therapeutics (NASDAQ:LPTX) announced positive updated data from its Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy, compared to bevacizumab...
Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic...
Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval...
Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a...
Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite...
Ondine Biomedical (LON:OBI) announced the initiation of patient recruitment for an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. The company states that...